KMB — Kimberly-Clark Corporation

The tape is decisively bearish even though the sell-side is only lukewarm. As of 2026-09-13 the stock had fallen 9.9% over the prior month and 6.5% in the prior week, and it sits 8.34% below its 20-day SMA. The trigger was Q2 2026 results (reported 2026-08-04), where GAAP diluted EPS of $1.04 landed far below the $2.12 adjusted figure because of transaction/restructuring charges, and Q2 operating margin compressed to 10.7% from 14.2% a year earlier. Layer on a stretched balance sheet (debt/equity 3.72, current ratio 0.909), the pending Kenvue transaction and the Arbex/Suzano JV reshaping the reported earnings base, and persistent input-cost inflation, and the sell-side has settled at a Hold consensus (9 buy / 19 hold / 3 sell) with a $112.25 target while the market has de-rated the shares first.

Revenue is flat-to-down and the mix has been reshaped by portfolio moves rather than demand. Quarterly sales ran $5.13B (Q3'23), $4.97B (Q4'23), $5.15B (Q1'24), $4.23B (Q2'24), $4.14B (Q3'24), $4.93B (Q4'24), $4.84B (Q1'25), $4.16B (Q2'25), $4.13B (Q3'25), $4.08B (Q4'25), $4.16B (Q1'26), $4.19B (Q2'26). The big step-down between Q1'25 ($4.84B) and Q1'26 ($4.16B) is the International Family Care/Professional separation plus the Arbex JV, not organic collapse - the last four quarters sit in a narrow $4.08-4.19B band and Q2'26 grew 0.6% year over year. Gross margin is actually improving, from 35.0% in Q2'25 to 38.3% in Q2'26. But operating margin is compressing hard: 15.9% (Q1'25), 14.2% (Q2'25), 15.0% (Q3'25), 12.4% (Q4'25), 11.4% (Q1'26), 10.7% (Q2'26). That combination - gross margin up, operating margin down roughly 500bp year over year - points to below-the-line charges (deal costs, restructuring, SG&A) rather than core pricing or input-cost failure. GAAP EPS is noisy across the last 12 quarters ($1.04 to $2.69) and TTM EPS of $5.88 materially understates the $2.12 adjusted Q2'26 run-rate. Free cash flow is the real soft spot: TTM FCF of $1.76B is down about 16% from $2.10B a year earlier, largely because quarterly capex roughly doubled, from ~$200M to $352M and $424M in the first two quarters of 2026. Verdict: stable top line, a charge-distorted earnings line, and a genuinely deteriorating cash-flow line.

Cheap versus its own history, fair-to-slightly-cheap versus the sector. As of 2026-09-13, the TTM P/E of 16.7x is a 22% discount to KMB's 5-year average of 21.5x, and the forward P/E of ~13.2x on the $7.419 next-FY consensus EPS is a ~38% discount to that average. P/S of 1.97x is below the 5-year average of 2.18x, and the 4.86% dividend yield is well above where this name has historically traded. Two caveats a fixed screen will get wrong: the PEG of -0.87 is meaningless because trailing growth is negative, and P/B of 18.7x is a buyback artifact (stockholders' equity of just $1.75B) rather than a valuation signal. On EV/EBITDA of 12.5x the stock looks closer to market-average than cheap - so the 'cheap' case rests almost entirely on the market believing a $7.42 forward EPS number that is 26% above trailing GAAP EPS.

The entire debate is whether trailing GAAP earnings represent real earnings power. TTM GAAP EPS is $5.88; next-FY consensus is $7.419; Q2 2026 adjusted EPS alone was $2.12 versus $1.04 GAAP. At $98.15, the market is capitalizing roughly $5.90 of earnings at 16.7x - effectively treating the $1.08/share of Q2 charges as permanent. If those charges roll off and EPS lands anywhere near $7.00-7.42, the same $98 price is only 13.2-14.0x, and even a mid-teens multiple gets you to $105-115. Conversely, if operating margin stays near 11% instead of recovering toward the 14-16% of 2024/2025, the $7.42 estimate is unreachable and $98 is fairly valued at best. This is a bet on margin normalization, and the Q3 2026 print (late October / early November 2026) is the first hard test.

Clearly oversold inside a clear downtrend as of 2026-09-13: RSI(14) of 28.26, price 8.34% below the 20-day SMA, 9.86% below the 50-day, and 4.86% below the 200-day, with -6.49% over one week and -9.9% over one month but only -0.7% over six months - meaning the damage is recent and concentrated, and the 200-day break is fresh rather than mature. There is no base, no positive divergence, and no reclaim of any moving average, so this is a falling-knife setup rather than a confirmed reversal. Tactically, RSI below 30 plus a 52-week low at $92.42 (about 6% below) argues for patience: the risk/reward only improves if price stabilizes back above the 20-day SMA or the Q3 print shows margin stabilization.

• Input-cost and energy inflation (pulp, resins, oil-linked freight) - management is leaning on 'aggressive internal gross productivity savings' to hold margins, and the ~500bp operating-margin decline says that offset is not yet winning.
• Consumer value-seeking and private-label expansion in tissue, baby care, and feminine care - KMB is answering with tiered innovation (Pull-Ups Learning Layers, Kleenex Snap & Go) rather than price cuts, which protects mix but caps volume upside.
• Cost of capital and rates - a $6.47B long-term debt stack plus a large pending acquisition makes this unusually rate-sensitive for a staples name; against only $1.76B of TTM free cash flow, refinancing costs matter a lot.
• FX translation - International Personal Care was the strongest segment in Q2 2026, so a strong dollar is a live swing factor on reported revenue and margins.
• Staples-versus-bonds rotation - a 4.86% yield makes KMB a bond proxy that competes directly with cash yields and gets hit when investors rotate out of defensives.

• Q3 2026 earnings (late October / early November 2026) - the first real read on whether the ~10.7% operating margin is a trough or the new normal, and whether productivity savings are catching input costs.
• Close of the pending Kenvue transaction, targeted by management for end-2026 - financing structure, pro-forma leverage, and synergy guidance will reset the entire earnings base and comparison set.
• Arbex (Suzano joint venture) ramp plus the new U.S. Southwest alternative-natural-fibers pilot plant - long-run structural cost and sustainability positioning.
• Capital returns: the $1.28/quarter dividend (4.86% yield) and any buyback resumption - though at roughly 97% of TTM free cash flow, the payout has very little room.
• A 2027 guidance reset or disclosure on the final economics of the IFP separation, which would clean up the comparability problem currently muddying the trailing numbers.

• Balance-sheet fragility: debt/equity of 3.72 with stockholders' equity of only $1.75B and a current ratio of 0.909 - there is almost no equity cushion, and a large acquisition would push leverage further.
• Dividend coverage: roughly $1.7B of annual dividends against $1.76B of TTM free cash flow is close to a 97% payout; any further FCF decline or capex step-up puts the payout at risk.
• Structural margin erosion: operating margin fell from 15.9% in Q1'25 to 10.7% in Q2'26. If input-cost inflation outruns productivity savings, the $7.42 forward EPS consensus is unreachable.
• Private-label and value-seeking share loss in tissue and baby care, KMB's highest-margin categories.
• Deal and integration risk from the pending Kenvue transaction and the IFP/Arbex restructuring, including the possibility of dilutive financing or a leverage-driven credit downgrade.
• Capex roughly doubling (from ~$200M per quarter to $352-424M in H1 2026) permanently lowers the free-cash-flow ceiling unless those projects earn their cost of capital.

Not a buy at $98.15, and probably not a sell either - this is a cheap, deeply oversold staple whose reported numbers are being mangled by one-off charges. The bull case is mechanical: 13.2x forward EPS, a 4.86% yield, an expanding gross margin (38.3% in Q2'26 versus 35.0% a year earlier), ROIC of 17.4%, and an accruals ratio of -3.03% (cash conversion is genuinely fine). The bear case is that operating margin has compressed ~500bp year over year, TTM free cash flow is down 16%, the dividend consumes roughly all of it, and a transformative acquisition is pending against an already razor-thin equity base. I would want one quarter of operating-margin stabilization before paying up, which makes the late-October/early-November 2026 Q3 print the decision point.

I blended two approaches as of 2026-09-13 and weighted 60/40 toward earnings: (a) 15.5x - a deliberate discount to KMB's 5-year average P/E of 21.5x and to staples peers, justified by 3.72x debt/equity, ~97% FCF dividend coverage and pending-deal risk - applied to a haircut forward EPS of $7.10 (below the $7.419 consensus) gives $110.05; (b) 12.8x EV/EBITDA (a touch above the current 12.5x) on roughly $3.04B of EBITDA, less ~$6.0B of net debt, over ~332M shares gives $99.10. The 60/40 blend is $106.